Comparison · NCT02470091-deaths
Cohort 1: Measurable vs Cohort 2: Resection: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Cohort 1: Measurable vs Cohort 2: Resection: deaths from any cause. Trial comparisons, record NCT02470091-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02470091-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.867 | 0.621 | 0.963 | wilson | |
| Risk in group 2 | 0.526 | 0.373 | 0.675 | wilson | |
| Risk difference, group 1 minus group 2 | 0.34 | 0.0532 | 0.522 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.65 | 1.15 | 2.36 | log | |
| Odds ratio, group 1 over group 2 | 5.85 | 1.16 | 29.5 | log | |
| Number needed to harm, for one more death from any cause on Cohort 1: Measurable than on Cohort 2: Resection | 2.94 | 1.92 | 18.8 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Cohort 1: Measurable | Cohort 1 patients must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 | 13 | 15 | EG000 |
| Group 2 | Cohort 2: Resection | Cohort 2 patients must have had a complete resection of all sites of metastatic disease within 30 days prior to enrollment | 20 | 38 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Through completion protocol therapy planned as 728 days after study enrollment
Source ClinicalTrials.gov
Trial
- Title
- Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
- NCT number
- NCT02470091
- Phases
- PHASE2
- Conditions
- Metastatic Osteosarcoma, Recurrent Osteosarcoma, Refractory Osteosarcoma, Stage IV Osteosarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7
- Interventions
- Denosumab, Laboratory Biomarker Analysis, Pharmacological Study
- Lead sponsor
- Children's Oncology Group
- Results first posted
- 2021-02-21
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02470091?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02470091-deaths